Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model

Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model

Targeted thorium-227 conjugates (TTCs) represent a novel class of therapeutic radiopharmaceuticals for the treatment of cancer. TTCs consist of the alpha particle emitter thorium-227 complexed to a 3,2-hydroxypyridinone chelator conjugated to a tumor-targeting monoclonal antibody. The high energy an...

Full description

Bibliographic Details
Main Authors: Katrine Wickstroem, Jenny Karlsson, Christine Ellingsen, Véronique Cruciani, Alexander Kristian, Urs B. Hagemann, Roger M. Bjerke, Olav B. Ryan, Lars Linden, Dominik Mumberg, Michael Brands, Alan Cuthbertson
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Pharmaceuticals
Subjects:
targeted thorium-227 conjugate
her2-ttc
dna damage response
thorium-227
targeted alpha therapy
Online Access:https://www.mdpi.com/1424-8247/12/4/155

Internet

https://www.mdpi.com/1424-8247/12/4/155

Similar Items